Adicet Bio, Inc.
ACET
$0.671
-$0.053-7.32%
| Weiss Ratings | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.72 | |||
| Price History | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -24.18% | |||
| 30-Day Total Return | -32.90% | |||
| 60-Day Total Return | -38.44% | |||
| 90-Day Total Return | -30.62% | |||
| Year to Date Total Return | -31.09% | |||
| 1-Year Total Return | -70.31% | |||
| 2-Year Total Return | -88.23% | |||
| 3-Year Total Return | -96.61% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -69.83% | |||
| 52-Week Low % Change | 4.72% | |||
| Price | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.40 | |||
| 52-Week Low Price | $0.69 | |||
| 52-Week Low Price (Date) | Apr 02, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 59.86M | |||
| Enterprise Value | -99.20M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.34 | |||
| Earnings Per Share Growth | -59.75% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.32 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.67 | |||
| Enterprise Value/EBITDA (TTM) | 0.82 | |||
| Enterprise Value/EBIT | 0.78 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 90.85M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 503 9095 | |||
| Address | 131 Dartmouth Street Boston, MA 02116 | |||
| Website | www.adicetbio.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -37.31% | |||
| Return on Equity | -- | |||
| Income Statement | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -121.15M | |||
| EBIT (TTM) | -127.62M | |||
| Net Income (TTM) | -117.12M | |||
| Net Income Avl. to Common (TTM) | -117.12M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 2.58% | |||
| EPS Diluted (TTM) | -1.34 | |||
| EPS Diluted Growth (Q YOY) | 53.85% | |||
| Balance Sheet | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 176.30M | |||
| Cash Per Share (Q) | $1.94 | |||
| Total Current Assets (Q) | 180.14M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 186.61M | |||
| Current Ratio (Q) | 9.289 | |||
| Book Value Per Share (Q) | $2.26 | |||
| Total Assets (Q) | 220.22M | |||
| Total Current Liabilities (Q) | 19.39M | |||
| Total Debt (Q) | 17.23M | |||
| Total Liabilities (Q) | 33.61M | |||
| Total Common Equity (Q) | 186.61M | |||
| Cash Flow | ACET - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -119.24M | |||
| Cash from Financing (TTM) | 111.31M | |||
| Net Change in Cash (TTM) | -100.31M | |||
| Levered Free Cash Flow (TTM) | -53.22M | |||
| Cash from Operations (TTM) | -92.38M | |||
